Plaintiffs had argued that the company knew that Zantac’s active ingredient, ranitidine, turned into the potential carcinogen NDMA under certain conditions. The US Food and Drug Administration ...

UK pharmaceutical giant GSK says it will pay as much as $2.2bn (£1.68bn) to settle thousands of cases in US courts over claims that a discontinued version of its heartburn drug Zantac caused cancer.

The four being recalled are Zantac 150mg/10ml Syrup ... all products which may contain the active pharmaceutical ingredient (API) that is potentially affected by this issue.

How do you explain one Zantac manufacturer kiboshing a favorable trend of defense verdicts and decisions – with a massive $2.2 billion settlement? The answer appears to lie with the whistleblower suit ...

GSK has struck a $2.2 billion agreement to settle the vast majority of U.S. lawsuits filed against it over claims its Zantac heartburn remedy causes cancer. The British drugmaker’s settlement ...

The first lawsuit claiming that gastrointestinal drug Zantac causes cancer has been voluntarily dismissed a week before it was due to come to trial, in an early victory for the pharma companies ...

Thousands of lawsuits have been filed against GSK, claiming their antacid Zantac caused a greater risk of cancer in its users, stating the main ingredient Ranitidine may be a human carcinogen.

A hearing will get underway in Delaware later today in the latest phase of GSK’s attempts to defend itself from allegations that its Zantac drug caused cancer in patients. The three-day hearing ...

In 2020, US regulators halted the sale of Zantac over concerns that a key ingredient, ranitidine, had the potential to turn into a substance that may trigger cancer when exposed to heat.

(WJET/WFXP) — UK-based pharmaceutical giant GSK, or GlaxoSmithKline, has announced that it has agreed to settle nearly 80,000 state-level Zantac cases. The lawsuits claimed that the now ...